科华生物
(002022)
| 流通市值：30.45亿 | | | 总市值：30.45亿 |
| 流通股本：5.14亿 | | | 总股本：5.14亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 395,096,525.16 | 1,642,485,860.08 | 1,191,260,566.76 | 793,574,870.31 |
| 营业收入 | 395,096,525.16 | 1,642,485,860.08 | 1,191,260,566.76 | 793,574,870.31 |
| 二、营业总成本 | 437,618,477.31 | 2,015,713,933.66 | 1,395,129,544.97 | 907,300,284.93 |
| 营业成本 | 249,672,613.44 | 1,066,290,182.88 | 764,646,192.49 | 496,885,326.02 |
| 税金及附加 | 1,152,470.61 | 10,723,779.31 | 8,147,903.74 | 5,424,225.38 |
| 销售费用 | 77,099,413.46 | 388,843,258.73 | 268,506,204.17 | 183,936,650.64 |
| 管理费用 | 65,734,027.99 | 342,505,973.07 | 228,697,454.09 | 143,017,855.95 |
| 研发费用 | 35,107,505.29 | 189,624,382.13 | 114,226,587.57 | 73,631,500.57 |
| 财务费用 | 8,852,446.52 | 17,726,357.54 | 10,905,202.91 | 4,404,726.37 |
| 其中:利息费用 | 6,747,857.94 | 23,324,872.37 | 19,271,096.52 | 12,178,726.7 |
| 其中:利息收入 | 779,856.4 | 6,449,721.86 | 5,093,554.87 | 3,498,867.99 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -20,109 | 32,174.4 | 13,984.75 | -19,103.55 |
| 加:投资收益 | 1,698,341.86 | 1,686,331.97 | 1,056,127.82 | 715,257.64 |
| 资产处置收益 | 850,902.47 | 3,869,704.67 | 2,631,988.46 | 2,344,755.76 |
| 资产减值损失(新) | -981,230.12 | -305,448,001.29 | -35,199,092.61 | -21,392,766.4 |
| 信用减值损失(新) | -4,761,559.88 | -153,057,245.35 | -27,534,853.98 | -11,004,933.29 |
| 其他收益 | 3,943,226.68 | 17,917,774.94 | 12,168,202.69 | 7,650,284.85 |
| 四、营业利润 | -41,792,380.14 | -808,227,334.24 | -250,732,621.08 | -135,431,919.61 |
| 加:营业外收入 | 90,240.92 | 2,756,152.69 | 1,623,340.76 | 757,194.23 |
| 减:营业外支出 | 458,907.67 | 6,643,300.36 | 2,644,494.26 | 1,062,573.1 |
| 五、利润总额 | -42,161,046.89 | -812,114,481.91 | -251,753,774.58 | -135,737,298.48 |
| 减:所得税费用 | 1,240,436.72 | 72,679,411.53 | 2,066,196.37 | 4,379,386.86 |
| 六、净利润 | -43,401,483.61 | -884,793,893.44 | -253,819,970.95 | -140,116,685.34 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -43,401,483.61 | -884,793,893.44 | -253,819,970.95 | -140,116,685.34 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -48,451,272.77 | -732,140,993.54 | -232,532,785.65 | -133,452,683.41 |
| 少数股东损益 | 5,049,789.16 | -152,652,899.9 | -21,287,185.3 | -6,664,001.93 |
| 扣除非经常损益后的净利润 | -51,383,973.4 | -745,452,318.73 | -242,590,731.29 | -139,851,547 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.09 | -1.42 | -0.45 | -0.26 |
| (二)稀释每股收益 | -0.09 | -1.42 | -0.45 | -0.26 |
| 八、其他综合收益 | -12,048,291.49 | 19,571,301.35 | 25,828,113.66 | 29,352,996.43 |
| 归属于母公司股东的其他综合收益 | -12,035,671.83 | 19,585,239.96 | 25,828,164.64 | 29,356,162.58 |
| 九、综合收益总额 | -55,449,775.1 | -865,222,592.09 | -227,991,857.29 | -110,763,688.91 |
| 归属于母公司股东的综合收益总额 | -60,486,944.6 | -712,555,753.58 | -206,704,621.01 | -104,096,520.83 |
| 归属于少数股东的综合收益总额 | 5,037,169.5 | -152,666,838.51 | -21,287,236.28 | -6,667,168.08 |
| 公告日期 | 2026-04-28 | 2026-04-17 | 2025-10-30 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |